Gastrointestinal Stromal Tumor
76
2
4
49
Key Insights
Highlights
Success Rate
86% trial completion
Published Results
14 trials with published results (18%)
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
10.5%
8 terminated out of 76 trials
86.0%
-0.5% vs benchmark
13%
10 trials in Phase 3/4
29%
14 of 49 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 49 completed trials
Clinical Trials (76)
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate
PH 2 Pemigatinib in SDH-deficient GIST
Expanded Access to Everolimus, for an Individual Patient With GIST (Gastrointestinal Stromal Tumors)(CTMS#18-0019)
GIST: Assessment of Tumor Mutations and TKI Plasma Exposure
Long Term Effects of Tyrosine Kinase Inhibitor Therapy on Ovarian Reserve and Fertility in Patients With Chronic Myeloid Leukemia or Gastrointestinal Stromal Tumor
Imatinib Mesylate in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
Surgery in Treating Patients With Liver Metastasis From a Gastrointestinal Stromal Tumor
Nivolumab With or Without Ipilimumab in Treating Patients With Gastrointestinal Stromal Tumor That Is Metastatic or Cannot Be Removed by Surgery
SSG XXV: The Stop-GIST Trial; Discontinuation of Imatinib in Patients With Oligo-metastatic GIST
Prospective Multicenter Clinical Study of Neoadjuvant Imatinib Mesylate for Gastrointestinal Stromal Tumors
Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable GIST
Influence of an Acidic Beverage on the Imatinib Exposure After Major Gastrectomy
Neoadjuvant and Adjuvant Imatinib Mesylate in Treating Patients With Primary or Recurrent Malignant Gastrointestinal Stromal Tumor
Regorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumor
Clinical Outcome of Female Non-gastric Gastrointestinal Stromal Tumor
A Study on Non-invasive Early Diagnosis of Gastrointestinal Stromal Tumors and Differentiation of Benign and Malignant Nodules
A Study to Evaluate the Safety of Intuvax Administered Intra-tumorally in Patients With Gastrointestinal Stromal Tumors
A Continuation Study Using Sunitinib Malate For Patients Leaving Treatment On A Previous Sunitinib Study.
Dasatinib as First-Line Therapy in Treating Patients With Gastrointestinal Stromal Tumors